Citius Oncology, Stock Today
| CTOR Stock | 0.85 0.13 13.27% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Citius Oncology, is selling at 0.85 as of the 24th of November 2024; that is 13.27% down since the beginning of the trading day. The stock's lowest day price was 0.85. Citius Oncology, has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Citius Oncology, symbol was changed from TENK on 13th of August 2024. Equity ratings for Citius Oncology, are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of October 2024 and ending today, the 24th of November 2024. Click here to learn more.
Moving together with Citius Stock
Moving against Citius Stock
Citius Stock Highlights
| Older Symbol | TENK |
| CEO Chairman | Leonard Mazur |
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) |
| Financial Strength | |
Citius Oncology, (CTOR) is traded on NASDAQ Exchange in USA. It is located in 420 Lexington Avenue, New York, NY, United States, 10170 and employs 4 people. Citius Oncology, was previously known as TenX Keane Acquisition and was traded on NASDAQ Exchange under the symbol TENK. Citius Oncology, is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 116.23 M. Citius Oncology, conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 2 M outstanding shares of which 39.42 K shares are currently shorted by private and institutional investors with about 0.0 trading days to cover.
Check Citius Oncology, Probability Of Bankruptcy
Citius Oncology, Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Citius Oncology, market risk premium is the additional return an investor will receive from holding Citius Oncology, long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.13) | |||
| Jensen Alpha | (1.17) | |||
| Total Risk Alpha | (2.15) | |||
| Treynor Ratio | (5.85) |
Citius Stock Against Markets
Citius Oncology, Corporate Executives
Elected by the shareholders, the Citius Oncology,'s board of directors comprises two types of representatives: Citius Oncology, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Citius. The board's role is to monitor Citius Oncology,'s management team and ensure that shareholders' interests are well served. Citius Oncology,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Citius Oncology,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jaime Bartushak | CFO Treasurer | Profile |
Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.